Safety and tolerability of second-generation encapsulated cell (EC) biodelivery of nerve growth factor (NGF), NGC 0295, in patients with Alzheimer's disease

Trial Profile

Safety and tolerability of second-generation encapsulated cell (EC) biodelivery of nerve growth factor (NGF), NGC 0295, in patients with Alzheimer's disease

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Dec 2015

At a glance

  • Drugs NGC 0295 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Sponsors NsGene
  • Most Recent Events

    • 01 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top